Skip to content
Open access

Multi-axis metabolic 3D modelling identifies a distinct phenotype in double negative demyelinating disease

Sep 2026 · Journal of Neuroinflammation · 0 citations

TL;DR

This framework resolves overlapping and clinically ambiguous phenotypes, improves separation of progressive and seronegative cases, and reveals DN as a heterogeneous entity that is metabolically distinct from MS while demonstrating closer proximity to MOGAD.

Abstract

Accurate discrimination of inflammatory demyelinating diseases remains clinically challenging, particularly in seronegative cases where conventional diagnostic biomarkers are absent. Existing metabolomic studies have largely relied on pairwise classification approaches, which do not capture shared and disease-specific metabolic components across related disorders. Here, we investigated whether integrated metabolomics and lipidomics combined with a multi-axis modelling framework could resolve disease-specific and overlapping metabolic structure across inflammatory demyelinating diseases, including double-negative cases (DN). Serum samples from relapsing-remitting multiple sclerosis (RRMS, n  = 29), secondary progressive MS (SPMS, n  = 20), primary progressive MS (PPMS, n  = 4), aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-NMOSD; n  = 49), myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD; n  = 18), and DN cases ( n  = 41) were analysed using nuclear magnetic resonance (NMR) metabolomics and liquid chromatography-mass spectrometry (LC-MS) lipidomics. Independent supervised models were trained, and outputs were transformed to logit probabilities (P_MOGAD, P_AQP4-NMOSD, P_SPMS) to construct a three-dimensional metabolic disease space, into which all individuals were projected. The combined model showed strong discrimination across disease groups (MS vs. antibody-mediated disease AUC = 0.938; RRMS vs. NMOSD AUC = 0.962; RRMS vs. MOGAD AUC = 0.920), with lower separation for RRMS vs. SPMS (AUC = 0.887). In the two-axis space, RRMS, NMOSD, and MOGAD formed clearly distinct regions, while DN and SPMS cases associated with the MOGAD axis. Adding a third SPMS axis separated SPMS from DN and captured an additional progression-related component. The position in this 3D space reflects how closely individuals aligned with different disease components rather than forcing discrete classification. Key discriminatory features included myo-inositol, glucose, histidine, and lipid-related measures (phosphatidylcholines, high-density lipoproteins), with consistent differences between MS and antibody-mediated disease. Multi-axis probabilistic modelling defines a continuous metabolic disease space that captures both shared and disease-specific components across inflammatory demyelinating disorders. Rather than enforcing discrete classification, this framework resolves overlapping and clinically ambiguous phenotypes, improves separation of progressive and seronegative cases, and reveals DN as a heterogeneous entity that is metabolically distinct from MS while demonstrating closer proximity to MOGAD. The compatibility of this analytical approach with clinically deployable metabolomics platforms highlights its potential utility for improving disease classification and patient stratification in inflammatory demyelinating disorders.

Read PDF

Similar papers

Open access Oct 2026

Metabolomic Profiles Associated With Disease Severity in Multiple Sclerosis

Background and Objectives Sensitive, minimally invasive biomarkers that reflect functional decline in multiple sclerosis (MS) are still lacking. Untargeted metabolomic profiling allows unbiased discovery of circulating biomarkers and dysregulated biological pathways underlying MS onset and progression. We aimed to iden...

Fatemeh Siavoshi, Dimitrios C. Ladakis, Larissa Jank et al. · 0 citations
Open access Sep 2026

Plasma immune signatures associate with neurodegeneration in frontotemporal lobar degeneration

Plasma multiplex proteomics identified complementary dimensions of neuroaxonal injury and immune dysregulation across frontotemporal lobar degeneration-related syndromes and candidates for independent biomarker validation and mechanistic investigation are identified.

M. van Schaik, K. O. Lai, N. Shapiro et al. · 0 citations
Open access Nov 2026

Metabolomics-based central obesity identifies subtypes musculoskeletal disorders management

This study aimed to identify novel metabolic subtypes of central obesity using nuclear magnetic resonance (NMR) metabolomics data and evaluate their prospective associations with the incidence of four classic musculoskeletal disorders including sarcopenia, intervertebral disc disease, osteoporosis, and rheumatoid arthr...

Qiong Han, Yue Zhang, Jing Feng et al. · 0 citations
Open access Oct 2026

A quantitative disorder-phenotype atlas of inherited metabolic disorders reveals shared symptom spaces and group-specific hotspots.

This first-generation knowledgebase-level atlas quantifies reported disorder-level phenotype architecture rather than patient-level prevalence or natural history rather than patient-level prevalence or natural history and provides a scalable framework for phenotype standardization, diagnostic navigation, targeted curat...

Nenad Blau, J. Vockley, Carlos Ferreira · 0 citations
#protein folding Open access Oct 2026

Multiomics Profiling Supports Cathepsin B as a Protective Factor in White Matter Hyperintensities and Cognition

Background: White matter hyperintensities (WMH) are a common brain MRI marker of cerebral small vessel disease and a major risk factor for stroke and dementia, yet the molecular mechanisms governing lesion formation remain incompletely understood. We sought to identify circulating proteins that lie upstream of WMH and...

C. Rivier, Sebastián Díaz-Pérez, Gael Bories et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.